Safety and Efficacy of Vicriviroc (MK-7690) in Combination With Pembrolizumab in Patients With Advanced or Metastatic Microsatellite Stable Colorectal Cancer

Authors: Bessudo, Alberto, Haseeb, Abdul Mustajeeb, Reeves, James A., Zhu, Xiaofu, Wong, Lucas, Giranda, Vincent, Suttner, Leah, Liu, Fang, Chatterjee, Manash, Sharma, Sunil

Source: In Clinical Colorectal Cancer September 2024 23(3):285-294

Propensity score-integrated Bayesian prior approaches for augmented control designs: a simulation study

Authors: Wang, Xi, Suttner, Leah, Jemielita, Thomas, Li, Xiaoyun

Source: Journal of biopharmaceutical statistics. 32(1):170-190

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100172704483.0x000001&indx=1&recIds=ETOCvdc_100172704483.0x000001

Platform Trial Design with Incorporating Historical Data Dynamically
Joint statistical meetings

Authors: Bao, Weichao, Amit, Ohad, Paul, Sofia, Ashton, Teri, Wang, Karrie, Suttner, Leah

Source: JSM proceedings (CD-ROM edition). 2019:343-6

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCCN606205051&indx=1&recIds=ETOCCN606205051

Independent drug action and its statistical implications for development of combination therapies

Authors: Chen, Cong, Liu, Fang, Ren, Yixin, Suttner, Leah, Sun, Zhiping, Shentu, Yue, Schmidt, Emmett V.

Source: In Contemporary Clinical Trials November 2020 98

Measuring and Analyzing Length of Stay in Critical Care Trials

Authors: Harhay, Michael O., Ratcliffe, Sarah J., Small, Dylan S., Suttner, Leah H., Crowther, Michael J., Halpern, Scott D.

Source: Medical Care, 2019 Sep 01. 57(9), e53-e59.

Access URL: https://www.jstor.org/stable/26833926

Method for Evaluating Longitudinal Follow-Up Frequency: Application to Dementia Research
Joint statistical meetings

Authors: Suttner, Leah, Xie, Sharon X.

Source: JSM proceedings (CD-ROM edition). 2018:301-12

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCCN605170857&indx=1&recIds=ETOCCN605170857

Statistical estimation of white matter microstructure from conventional MRI

Authors: Suttner, Leah H, Mejia, Amanda, Dewey, Blake, Sati, Pascal, Reich, Daniel S, Shinohara, Russell T

Source: In NeuroImage: Clinical February 2016 12:615-623

Pembrolizumab plus enzalutamide for metastatic castration-resistant prostate cancer progressing on enzalutamide: cohorts 4 and 5 of the phase 2 KEYNOTE-199 study

Authors: Graff, Julie N., Hoimes, Christopher J., Gerritsen, Winald R., Vaishampayan, Ulka N., Elliott, Tony, Hwang, Clara, ten Tije, Albert J., Omlin, Aurelius, McDermott, Raymond S., Fradet, Yves, Tagawa, Scott T., Kilari, Deepak, Ferrario, Cristiano, Uemura, Hiroji, Jones, Robert J., Fukasawa, Satoshi, Peer, Avivit, Niu, Cuizhen, Poehlein, Christian H., Qiu, Ping, Suttner, Leah, de Wit, Ronald, Schloss, Charles, de Bono, Johann S., Antonarakis, Emmanuel S.

Source: Prostate Cancer and Prostatic Diseases; 20240101, Issue: Preprints p1-8, 8p

Testing patient-informed approaches for visually depicting the hemoglobin A1c value to patients with poorly controlled diabetes: a randomized, controlled trial

Authors: Gopalan, Anjali, Suttner, Leah, Troxel, Andrea B., McDonough, Kevin, Schapira, Marilyn M.

Source: BMC health services research. 20(1)

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100164292408.0x000001&indx=1&recIds=ETOCvdc_100164292408.0x000001

Results of an open-label phase 1b study of the ERK inhibitor MK-8353 plus the MEK inhibitor selumetinib in patients with advanced or metastatic solid tumors.

Authors: Stathis, Anastasios, Tolcher, Anthony W., Wang, Judy S., Renouf, Daniel J., Chen, Lin-Chi, Suttner, Leah H., Freshwater, Tomoko, Webber, Andrea L., Nayak, Tapan, Siu, Lillian L.

Source: Investigational New Drugs; Jun2023, Vol. 41 Issue 3, p380-390, 11p

Subject Terms: SMALL molecules, CLINICAL drug trials, CLINICAL trials, DRUG tolerance, ORAL drug administration, METASTASIS, ANTINEOPLASTIC agents, INVESTIGATIONAL drugs, TUMOR classification, TRANSFERASES, DESCRIPTIVE statistics, RESEARCH funding, MITOGEN-activated protein kinases, TUMORS, PATIENT safety, PHARMACODYNAMICS

Phase 1b/2 umbrella study of investigational immune and targeted combination therapies for patients with advanced clear cell renal cell carcinoma (ccRCC).

Authors: Motzer, Robert J., Albiges, Laurence, Choueiri, Toni K., Plimack, Elizabeth R., Rini, Brian I., Suttner, Leah, Yin, Lina, Willemann-Rogerio, Jacqueline, Hammers, Hans J.

Source: Journal of clinical oncology. 40(6 suppl):TPS404-TPS404

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100152992339.0x000001&indx=1&recIds=ETOCvdc_100152992339.0x000001

Association between biomarkers and clinical outcomes of lenvatinib + pembrolizumab in advanced renal cell carcinoma (RCC): Results from Study 111/KEYNOTE-146.

Authors: Lee, Chung-Han, Rasco, Drew W., Rao, Arpit, Taylor, Matthew H., Hsieh, James J, Pinto, Alvaro, Vogelzang, Nicholas J., Cao, Z. Alexander, Suttner, Leah, Loboda, Andrey, Vajdi, Amir, Predoiu, Raluca Andreia, Nebozhyn, Michael, Lunceford, Jared, Perini, Rodolfo F., Matsui, Junji, Minoshima, Yukinori, Dutcus, Corina E., Dutta, Lea, Motzer, Robert J.

Source: Journal of clinical oncology. 40(6 suppl):375-375

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100152991005.0x000001&indx=1&recIds=ETOCvdc_100152991005.0x000001

This result is not displayed to guests.
Login for full access.

A phase 1b/2 umbrella study of investigational immune and targeted combination therapies as first-line therapy for patients with advanced renal cell carcinoma (RCC).

Authors: Plimack, Elizabeth R., Hammers, Hans J., Choueiri, Toni K., Rini, Brian I., Motzer, Robert J., Suttner, Leah, Perini, Rodolfo F., Willemann Rogerio, Jaqueline, Albiges, Laurence

Source: Journal of clinical oncology. 39(15 suppl):TPS4594-TPS4594

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100173202958.0x000001&indx=1&recIds=ETOCvdc_100173202958.0x000001

This result is not displayed to guests.
Login for full access.

A randomized, double-blind, phase II study of MK-4280A (coformulation of favezelimab and pembrolizumab) plus lenvatinib versus pembrolizumab plus lenvatinib among patients with previously-treated mismatch repair proficient advanced endometrial cancer.

Authors: Girda, Eugenia¹ (AUTHOR), Makker, Vicky² (AUTHOR), Marth, Christian³ (AUTHOR), Van Gorp, Toon⁴ (AUTHOR), Mirza, Mansoor⁵ (AUTHOR), Shapira-Frommer, Ronnie⁶ (AUTHOR), Suttner, Leah⁷ (AUTHOR), Groisberg, Roman⁷ (AUTHOR), Jin, Fan⁷ (AUTHOR), O'Malley, David⁸ (AUTHOR)

Source: Gynecologic Oncology. 2024 Supplement 1, Vol. 190, pS293-S294. 2p.

Subject Terms: *ENDOMETRIAL cancer, *PEMBROLIZUMAB